Hydroxyapatite nanocrystals as a smart, pH sensitive, delivery system for kiteplatin

Prior research has shown that hydroxyapatite (HA) nanocrystals are naturally occurring inorganic structures found in vertebrate hard tissues. These nanocrystals have been explored for use in biomedical applications such as bone substitutes or coatings for prostheses. It was already known that HA can bind various therapeutic agents and biomolecules, making it a candidate for drug delivery systems. However, the specific application of HA as a pH-sensitive carrier for platinum-based anticancer drugs remained unexplored. This gap motivated the investigation of HA's potential to deliver platinum derivatives selectively in acidic tumor environments. No prior work had resolved how HA's pH-dependent solubility could be harnessed for targeted drug release. The study aimed to address this uncertainty by examining the adsorption and release behavior of platinum compounds from HA nanocrystals. The goal was to determine if HA could serve as a smart delivery system that releases drugs only in acidic tumor microenvironments.

The aim of the study was to assess the feasibility of using hydroxyapatite (HA) nanocrystals as a pH-sensitive drug delivery system for platinum-based anticancer agents. The researchers focused on two platinum derivatives of cis-1,4-diaminocyclohexane ([PtX2(cis-1,4-DACH)], X2 = Cl2 (1) and 1,1-cyclobutanedicarboxylate (CBDCA, 2)). The first compound showed activity against colon cancer cells resistant to oxaliplatin, making it a promising candidate for testing. The study sought to determine how these compounds interact with HA nanocrystals in terms of adsorption and release. The researchers also aimed to evaluate how pH influences the release of these drugs from HA matrices. The motivation stemmed from HA's known pH-dependent solubility, which could allow drug release in acidic tumor environments. The study's specific problem was to determine if HA could serve as a bone-specific drug delivery system that releases platinum compounds selectively in acidic conditions.

The study used biomimetic hydroxyapatite (HA) nanocrystals as the drug delivery platform. Two platinum derivatives of cis-1,4-diaminocyclohexane were tested: [PtCl2(cis-1,4-DACH)] (compound 1) and [Pt(CBDCA)(cis-1,4-DACH)] (compound 2). The researchers first examined the adsorption of these compounds onto HA nanocrystals. They then investigated the release of the compounds from HA matrices under varying pH conditions to simulate physiological environments. The pH levels were chosen to represent healthy tissues and tumor microenvironments. The in vitro cytotoxicity of the released compounds was assessed using various human cancer cell lines. The experimental setup included controlled pH environments to mimic the acidic conditions found in tumors. The researchers used analytical methods to measure drug adsorption and release kinetics. The study design focused on determining the pH-dependent release behavior of the platinum compounds from HA nanocrystals.

The study found that hydroxyapatite (HA) nanocrystals effectively adsorbed both platinum derivatives of cis-1,4-diaminocyclohexane. The release of these compounds from HA matrices was strongly influenced by pH. At lower pH levels, such as those found in tumor microenvironments, the release of the platinum compounds was significantly accelerated. In contrast, at physiological pH levels, the release was minimal, confirming HA's pH-dependent solubility. The first compound ([PtCl2(cis-1,4-DACH)]) showed activity against colon cancer cells resistant to oxaliplatin, suggesting its potential as an anticancer agent. The in vitro cytotoxicity tests confirmed that the releasates from HA matrices retained their anticancer activity. The results demonstrated that HA nanocrystals could function as a smart delivery system that releases drugs selectively in acidic tumor environments. The findings fully confirmed the potential of HA nanocrystals loaded with the first compound as a bone-specific drug delivery device.

The authors concluded that hydroxyapatite (HA) nanocrystals have the potential to serve as a pH-sensitive drug delivery system for platinum-based anticancer agents. The study demonstrated that HA nanocrystals can adsorb platinum derivatives of cis-1,4-diaminocyclohexane and release them selectively in acidic tumor environments. The pH-dependent solubility of HA allows for controlled drug release in regions with lower pH, such as those found in tumors. The first compound ([PtCl2(cis-1,4-DACH)]) showed activity against colon cancer cells resistant to oxaliplatin, supporting its potential as an anticancer agent. The in vitro cytotoxicity tests confirmed that the releasates from HA matrices retained their anticancer activity. The findings suggest that HA nanocrystals could be used as a bone-specific drug delivery system that releases drugs in acidic tumor microenvironments. The study's results fully confirmed the potential of HA nanocrystals loaded with the first compound as a smart delivery system for anticancer drugs.